Glaukos Co. (NYSE:GKOS) Stock Position Raised by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lifted its position in Glaukos Co. (NYSE:GKOS) by 12.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,770 shares of the medical instruments supplier’s stock after buying an additional 661 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Glaukos were worth $865,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC grew its position in Glaukos by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after acquiring an additional 89 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after purchasing an additional 91 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $4,003,000 after purchasing an additional 100 shares in the last quarter. Handelsbanken Fonder AB increased its position in Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock worth $2,204,000 after buying an additional 100 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Glaukos by 2.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,956 shares of the medical instruments supplier’s stock valued at $1,427,000 after buying an additional 231 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Wells Fargo & Company increased their price objective on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Stifel Nicolaus increased their price target on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Truist Financial raised their target price on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler reissued an “overweight” rating and set a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Stock Performance

NYSE:GKOS opened at $97.15 on Wednesday. The firm’s 50-day moving average is $128.12 and its 200-day moving average is $135.38. The company has a market cap of $5.50 billion, a price-to-earnings ratio of -33.85 and a beta of 0.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52-week low of $88.16 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Equities research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.